Q-omics provides the consensus-scored TMEM270 profile across patient tissues and cancer cell-line models. TMEM270 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM270 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TMEM270 RNA expression shows 12,622 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where TMEM270 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM270 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM270 survival associations across molecular data types. TMEM270 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM270 RNA expression–survival associations across cancer types. High TMEM270 expression shows unfavorable associations in MESO, LGG, ACC, PAAD, ESCA and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM270 RNA expression.
This table summarizes TMEM270 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM270. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM270 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRP, HNSC, STAD and THCA. The COAD box plot shows higher TMEM270 RNA expression in tumor versus normal tissue (log2 FC = +0.799, t-test p < 0.001).
This table shows molecular features associated with TMEM270 in patient tissues and cancer cell lines. In patient samples, TMEM270 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM270 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_SCLC.
